source
- Avalyn Pharma targets $182M IPO as WHO prequalifies Novartis malaria drugAvalyn Pharma announced plans for an initial public offering that could raise about $182 million in net proceeds. The company is developing inhaled formulations of drugs already approved for pulmon…
- Novartis withdraws EU filing for Pluvicto label expansion into early-stage prostate cancerNovartis announced it has pulled its application to the European Medicines Agency to extend the label of its radioligand therapy Pluvicto for use in earlier stages of prostate cancer. The move com…